Stock Track | GENFLEET-B Soars 5.34% Intraday as Key Drug Added to China's National Reimbursement List

Stock Track03-25

Shares of GENFLEET-B (02595) surged 5.34% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.

The sharp increase appears to be driven by the announcement that Genfleet Therapeutics' KRAS G12C inhibitor, fulzerasib, has been added to China's national drug reimbursement list. This marks the company's first marketed product in mainland China, with coverage scheduled to take effect in 2026, potentially expanding patient access and driving future revenue growth.

Genfleet also reported advancing multiple RAS-targeted programs in its pipeline, including a KRAS G12D candidate, which could support broader partnering opportunities and future commercialization plans for the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136203088?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136203088","market":"us","top_or_hot":-1,"title":"Stock Track | GENFLEET-B Soars 5.34% Intraday as Key Drug Added to China's National Reimbursement List","media":"Stock Track","content":"<p>Shares of GENFLEET-B (02595) surged 5.34% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.</p><p>The sharp increase appears to be driven by the announcement that Genfleet Therapeutics' KRAS G12C inhibitor, fulzerasib, has been added to China's national drug reimbursement list. This marks the company's first marketed product in mainland China, with coverage scheduled to take effect in 2026, potentially expanding patient access and driving future revenue growth.</p><p>Genfleet also reported advancing multiple RAS-targeted programs in its pipeline, including a KRAS G12D candidate, which could support broader partnering opportunities and future commercialization plans for the company.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GENFLEET-B Soars 5.34% Intraday as Key Drug Added to China's National Reimbursement List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GENFLEET-B Soars 5.34% Intraday as Key Drug Added to China's National Reimbursement List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-25 10:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of GENFLEET-B (02595) surged 5.34% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.</p><p>The sharp increase appears to be driven by the announcement that Genfleet Therapeutics' KRAS G12C inhibitor, fulzerasib, has been added to China's national drug reimbursement list. This marks the company's first marketed product in mainland China, with coverage scheduled to take effect in 2026, potentially expanding patient access and driving future revenue growth.</p><p>Genfleet also reported advancing multiple RAS-targeted programs in its pipeline, including a KRAS G12D candidate, which could support broader partnering opportunities and future commercialization plans for the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"劲方医药-B","start_time":0,"source_url":"","article_id":"1136203088","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136203088","pubTimestamp":1774404047,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of GENFLEET-B (02595) surged 5.34% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.The sharp increase appears to be driven by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02595":"劲方医药-B"},"translate_title":"个股追踪|GENFLEET-B盘中大涨5.34%关键药物加入中国国家报销目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":1},"content_text":"Shares of GENFLEET-B (02595) surged 5.34% during intraday trading on Wednesday, marking a significant upward movement for the biotechnology company.The sharp increase appears to be driven by the announcement that Genfleet Therapeutics' KRAS G12C inhibitor, fulzerasib, has been added to China's national drug reimbursement list. This marks the company's first marketed product in mainland China, with coverage scheduled to take effect in 2026, potentially expanding patient access and driving future revenue growth.Genfleet also reported advancing multiple RAS-targeted programs in its pipeline, including a KRAS G12D candidate, which could support broader partnering opportunities and future commercialization plans for the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136203088","isCrawlerRequest":true}